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Abstract
Introduction: Exercise training has emerged as a promising therapeutic strategy to counteract physical dysfunction
in adult systemic lupus erythematosus. However, no longitudinal studies have evaluated the effects of an exercise
training program in childhood-onset systemic lupus erythematosus (C-SLE) patients. The objective was to evaluate
the safety and the efficacy of a supervised aerobic training program in improving the cardiorespiratory capacity in
C-SLE patients.
Methods: Nineteen physically inactive C-SLE patients were randomly assigned into two groups: trained (TR, n = 10,
supervised moderate-intensity aerobic exercise program) and non-trained (NT, n = 9). Gender-, body mass index
(BMI)- and age-matched healthy children were recruited as controls (C, n = 10) for baseline (PRE) measurements
only. C-SLE patients were assessed at PRE and after 12 weeks of training (POST). Main measurements included
exercise tolerance and cardiorespiratory measurements in response to a maximal exercise (that is, peak VO2,
chronotropic reserve (CR), and the heart rate recovery (ΔHRR) (that is, the difference between HR at peak exercise
and at both the first (ΔHRR1) and second (ΔHRR2) minutes of recovery after exercise).
Results: The C-SLE NT patients did not present changes in any of the cardiorespiratory parameters at POST (P >
0.05). In contrast, the exercise training program was effective in promoting significant increases in time-to-
exhaustion (P = 0.01; ES = 1.07), peak speed (P = 0.01; ES = 1.08), peak VO2 (P = 0.04; ES = 0.86), CR (P = 0.06; ES =
0.83), and in ΔHRR1 and ΔHRR2 (P = 0.003; ES = 1.29 and P = 0.0008; ES = 1.36, respectively) in the C-SLE TR when
compared with the NT group. Moreover, cardiorespiratory parameters were comparable between C-SLE TR patients
and C subjects after the exercise training intervention, as evidenced by the ANOVA analysis (P > 0.05, TR vs. C).
SLEDAI-2K scores remained stable throughout the study.
Conclusion: A 3-month aerobic exercise training was safe and capable of ameliorating the cardiorespiratory
capacity and the autonomic function in C-SLE patients.
Trial registration: NCT01515163.
Introduction
Systemic lupus erythematosus (SLE) is a life-long sys-
temic autoimmune disease with a large variability in its
clinical course. The onset of SLE during childhood and
adolescence represents 10 to 20% of all SLE cases [1] and
is associated with a more severe disease course compared
to adult SLE. Due to earlier diagnosis as well as signifi-
cant advances in the management of childhood-onset
SLE (C-SLE), mortality rates have greatly decreased, with
an estimated 5- to 10-year survival rate of over 85% [2].
As a consequence, there has been a great increase in
long-term co-morbidities, particularly cardiovascular dis-
ease (CVD), which is currently considered a major cause
of long-term mortality in C-SLE patients [3].
Both disease-related (namely, long-term corticosteroid
use, systemic inflammation, and autonomic dysfunction)
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and traditional factors (namely, lipid abnormalities, dia-
betes mellitus, and hypertension) have been implicated
in the increased CVD risk in SLE [4-7]. Additionally,
SLE patients commonly present a reduced exercise
capacity and physical function [8-12], which may further
increase CVD and mortality risk [13].
In this context, exercise training has emerged as a
potential non-pharmacological therapeutic strategy to
counteract physical dysfunction in adult SLE [8,9,14-16],
although no studies have been conducted with C-SLE
patients. It is well-known that exercise-induced adapta-
tions largely differ between adults and children. This holds
true for a variety of training variables, including (but not
limited to) maximal aerobic capacity, mechanical efficiency
and economy of movement, anaerobic capacity, exercise
recovery, cardiovascular response, strength, immune
response, morphological adaptations, detraining, metabolic
responses, thermal regulation, etcetera. Such discrepant
responses rely on physiological, metabolic, maturational,
social, affective, and perceptual characteristics that are
unique to pediatric populations [17]. Additionally, it has
been also recognized that C-SLE patients may show differ-
ential features compared with adult counterparts, espe-
cially in regard to clinical symptoms and treatment
response [18-21]. In light of these factors, one may suggest
that the exercise training-induced outcomes found in the
adult SLE population cannot be promptly generalized to
C-SLE, thus warranting studies in this specific population.
A few studies have demonstrated the beneficial role of
exercise in other pediatric rheumatic diseases, including
juvenile dermatomyositis (JDM) [22,23] and fibromyalgia
[24]. Furthermore, we recently demonstrated that a three-
month supervised aerobic training program was effective
in improving the aerobic capacity and the physical func-
tion of a 15-year-old boy with C-SLE associated with sec-
ondary antiphospholipid syndrome [25]. However, to the
best of our knowledge, no longitudinal studies have evalu-
ated the potential therapeutic effects of an exercise train-
ing program in the C-SLE population [26].
Thus, the aim of the present study was to evaluate the
safety and the efficacy of a 12-week supervised aerobic
training program in improving the cardiorespiratory
capacity in C-SLE patients.
Materials and methods
Experimental design and patients
A 12-week randomized trial was conducted between May
2010 and April 2011 at the Laboratory of Physical Condi-
tioning in Rheumatology of the School of Medicine,
University of Sao Paulo, Brazil. This trial was registered
at clinicaltrials.gov as NCT01515163. The sample con-
sisted of children and adolescents with C-SLE from the
outpatient ambulatory of the Pediatric Rheumatology
Division of the Children’s Institute of the School of
Medicine, University of Sao Paulo, Brazil, who were
randomly assigned to participate in a three-month super-
vised exercise training program (trained, TR) or to
remain physically inactive (non-trained, NT). Randomiza-
tion was accomplished through a block randomization
procedure with block sizes of four individuals. Body mass
index-, gender- and age-matched healthy children from
the surrounding community were recruited as controls
(C). The patients fulfilled the revised American College of
Rheumatology criteria [27] for C-SLE. The inclusion cri-
teria were: age between 7 and 15 years, and Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI)-2K
score ≤ 16. Exclusion criteria included neuropsychiatry
involvement, hematologic abnormalities, cardiovascular
rhythm and conduction disorders, musculoskeletal distur-
bances that precluded participation in physical exercise,
pleuritis, pericarditis, endocarditis, acute kidney failure,
use of tobacco, treatment with lipid-lowering drugs, sec-
ondary fibromyalgia. Healthy control subjects were not
taking any medication. C-SLE patients had not engaged in
regular physical activity programs at least 6 months prior
to the study. Importantly, the healthy control subjects
were engaged only in the physical education classes in
school (a 45-minute session twice a week).
At baseline (PRE) and 12 weeks after the intervention
(POST), clinical (that is SLEDAI-2K [28] and Systemic
Lupus International Collaborating Clinics/ACR Damage
Index (SLICC/ACR-DI) [29], and laboratory parameters
(namely, erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP), complements 3 and 4 (C3 and C4) and
anti-dsDNA antibodies), cardiorespiratory measurements
in response to a maximal graded exercise, body composi-
tion, and bone mineral density (BMD) were assessed in
the C-SLE patients. Healthy children and adolescents were
assessed for the same aforementioned parameters only at
baseline. The study was approved by the Committee of
Ethics in Research of the General Hospital of the School
of Medicine, University of Sao Paulo, Brazil (CAPPesq)
and all of the subjects’ parents signed the informed
consent.
Exercise training program
The exercise program consisted of 12 weeks of twice-
weekly supervised moderate-intensity aerobic exercise
training. Training sessions comprised a 5-minute warm-
up followed by 20 to 50 minutes of treadmill aerobic train-
ing (a 10-minute increment in the aerobic training volume
was applied every four weeks), and 5 minutes of cool-
down on the treadmill at a low speed followed by stretch-
ing exercises. All of the training sessions were monitored
by at least one fitness professional and a Rheumatologist
monitored adverse events on a weekly basis. The exercise
program was performed in an intra-hospital gymnasium.
Aerobic training intensity was set at the corresponding
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heart rate between the ventilatory anaerobic threshold
(VAT) and 10% below the respiratory compensation point
(RCP). All of the patients were able to achieve the set
aerobic training intensity.
Cardiorespiratory exercise test
The cardiorespiratory exercise test was performed on a
treadmill (Centurion, model 200, Micromed, Brazil), using
a maximal graded exercise protocol [30]. The treadmill
speed (2.0, 2.5, 3.0, 3.5, 4.0, 4.0, 4.0, 4.0, 5.0, 5.4, 5.9, 6.3,
6.3 mph), or grade (0.0, 0.0, 0.0, 0.0, 0.0, 2.5, 5.0, 7.5, 4.0,
4.0, 4.0, 4.0. 5.8%) was increased every 1 minute. The
recovery period was set at 2 minutes. Oxygen consump-
tion (VO2) and carbon dioxide output were obtained
through breath-by-breath sampling and expressed as a
30-second average using an indirect calorimetry system
(Cortex, model Metalyzer III B, Leipzig, Germany). Heart
Rate (HR) was continuously recorded at rest, during exer-
cise, and at recovery, using a 12-lead electrocardiogram
(Ergo PC Elite, InC. Micromed, Brasília, DF, Brazil). Peak
oxygen consumption (peak VO2), VAT and RCP were
determined according to previously described criteria [30].
The test was deemed complete when despite verbal
encouragement, the child was unable to continue exercis-
ing. The following criteria were used to define maximal
effort: 1) subjective evidence of exhaustion and either 2)
peak HR > 190 beats/minute, or 3) maximal respiratory
exchange ratio (RER) > 1.00 [31].
HR response during exercise and recovery
HR response during exercise was evaluated by the
chronotropic reserve (CR) as follows [32]:
(
(CR) =
(
Peak HR − Resting HR/208 − (0.7 ∗ Age) − Resting HR] × 100) .
HR recovery was defined as the difference between
HR at peak and at both the first (ΔHRR1) and second
(ΔHRR2) minutes after exercise. Absolute change (Δ)
was used to calculate the difference between the HR at
peak exercise and at the first and second minutes after
the exercise test. The relative change in HR (Δ%) was
calculated for the intervals between rest to VAT, rest to
RCP, and rest to peak exercise.
BMD and body composition
BMD (g/cm2) was determined by dual-energy x-ray
absorptiometry (DXA), using a Hologic QDR 4500 Discov-
ery densitometer (Hologic Inc., Bedford, MA, USA). Bone
area (BA) (cm2) was calculated using the software pro-
vided with the densitometer. Bone mass was analyzed in
the lumbar spine (lumbar vertebrae L1 to L4), total femur,
and whole body. The whole-body analysis was conducted
without including the head, as it has been described to
increase variability in children [33]. To minimize the
confounding effect of skeletal size on DXA measurements,
a volumetric, three-dimensional approximation of bone
density was calculated (that is, bone mineral apparent den-
sity (BMAD) in g/cm3). BMAD was assessed by dividing
the BMD in a given site (the lumbar spine, total femur, or
whole body) by the square root of the corresponding bone
area (BA) (BMAD = BMD/√BA) [34]. All of the measure-
ments were performed by the same trained technologist.
Precision error for BMD measurements was determined
according to the standards in the International Society for
Clinical Densitometry protocols [35]. Least significant
changes with 95% confidence were 0.033 g/cm2 at the
lumbar spine, 0.039 g/cm2 at the total femur, and 0.020 g/
cm2 at the whole body. Body composition (that is, lean
mass and fat mass) was assessed through the same densit-
ometer, using pediatric software.
Statistical analysis
The data are presented as means and SDs. Fisher’s exact
test was used to assess baseline differences between the
C-SLE groups in the drug regimen. The disease-related
parameters (SLEDAI-2K, SLICC/ACR-DI, disease dura-
tion, and current and cumulative dose of drugs) at base-
line were compared using the Student’s t-test. After the
normality and homogeneity of the variance were con-
firmed, the dependent variables were compared using a
mixed model for repeated measures, assuming groups
and time as fixed factors and subjects as random factors.
Single degree of freedom contrasts were used to deter-
mine significant differences between groups. Finally,
effect sizes (ES) were estimated for the POST assess-
ments using the pooled SDs of the two independent sam-
ples at POST [36]. The significance level was set at P <
0.05. All of the analyses were performed using SAS 9.2,
SAS Institute Inc., Cary, NC, USA.
Results
Patients
Twenty C-SLE patients were randomly assigned to the
experimental groups (TR = 10 and NT = 10). One patient
from the NT group withdrew from the study due to perso-
nal reasons and was excluded from the analysis. Thus, 19
patients were included in the analysis (TR = 10, NT = 9)
(Figure 1). Ten healthy subjects were included in the
healthy control group (C = 10). Table 1 shows the demo-
graphic data of the C-SLE patients and healthy control
subjects at baseline. The groups were similar in age,
weight, height, BMI values, and drug regime at baseline
(P > 0.05). The exercise adherence rate was 94.0 ± 7.03%.
Exercise tolerance and cardiorespiratory measurements at
baseline
The exercise and cardiorespiratory parameters at base-
line are shown in Table 2. The C-SLE patients presented
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lower time-to-exhaustion, peak speed, peak VO2 and CR
during the cardiorespiratory exercise test and higher rest-
ing HR when compared with the healthy control subjects
(P < 0.05, between-group comparisons). In addition, the
relative change in HR (Δ%) from rest to VAT, rest to RCP,
and rest to peak of exercise, and the HR recovery (that is,
ΔHRR1 and ΔHRR2) were also significantly lower in the
C-SLE patients when compared with healthy controls (P <
0.05, between-group comparisons). Importantly, all of the
parameters were similar between the TR and NT groups
(P > 0.05, between-group comparisons).
Exercise tolerance and cardiorespiratory measurements
after the exercise training program
The exercise and cardiorespiratory parameters after
the exercise training program are shown in Table 2. As
expected, the NT group did not present any change in any
of the parameters (P < 0.05, within-group comparisons). In
contrast, the TR group presented significant increases in
time-to-exhaustion (P = 0.01, ES = 1.07) and peak speed
(P = 0.01, ES = 1.08) and a decrease in resting HR (P =
0.0002, ES = -1.45) when compared with the NT group.
Additionally, the TR group had increased peak VO2 (P =
0.04, ES = 0.86), CR (P = 0.06, ES = 0.83), relative change
in HR (Δ%) from rest to VAT (P = 0.0001, ES = 1.58, rest
to RCP (P = 0.0001, ES = 1.49), and rest to peak of exercise
(P = 0.0003, ES = 1.53), and ΔHRR1 (P = 0.003, ES = 1.29)
and ΔHRR2 (P = 0.0008, ES = 1.36) in comparison to the
NT group. Moreover, after the aerobic exercise training
program, the latter cardiorespiratory responses to exercise
were comparable between the trained group and the
healthy control group (P > 0.05) (Figures 2 and 3).
Clinical parameters, drug regimen, and adverse effects
SLEDAI-2K scores remained unchanged throughout the
study for both groups (TR: PRE = 5.0 ± 5.1, POST = 3.8 ±
3.8, P = 0.71, and NT: PRE = 5.5 ± 6.4, POST = 3.1 ± 3.8,
P = 0.20; within-group comparison).
Prednisone dosage was also unchanged in both groups
after the intervention (TR: PRE = 14.8 ± 11.1, POST =
12.5 ± 7.2 mg/day, P = 0.39, and NT: PRE = 13.8 ± 6.5,
POST = 12.5 ± 5.8 mg/day, P = 0.84; within-group com-
parisons). Similarly, the other drugs (type and dose of
medications) remained stable throughout the study. Addi-
tionally, the levels of ESR, CRP, C3 and C4 and anti-
DNAds antibodies were unaltered in both groups through-
out the study (P > 0.05, within-group comparison; data not
shown). Finally, there was no clinical evidence of excessive
Did not accept (n = 3) 
Did not meet the  
inclusion criteria  (n = 4) 
HEALTHY CONTROLS 
Met the inclusion criteria  
(n = 10) 
Allocated to healthy  
control group (n = 10) 
Healthy  control group  
(C; n = 10) 
Invited to participate 
(n = 20) 
C-SLE PATIENTS 
Withdrew for personal 
reasons  (n = 1) 
Non-trained  group  
(NT; n = 9) 
Allocated to trained 
group (n = 10) 
Trained  group  
(TR; n = 10) 
Allocated to non-
trained group (n = 10) 
Met the inclusion criteria  
(n = 20) 
Randomized   (n = 20) 
Invited to participate 
(n = 27) 
Did not accept (n = 10) 
Figure 1 Flow diagram of the patients. C-SLE, childhood-onset systemic lupus erythematosus.
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exhaustion, pain, osteoarticular injury, muscle soreness, or
any other adverse event.
BMD and body composition
The TR, NT and C groups were similar in body composi-
tion and BMD parameters at baseline (P > 0.05, between-
group comparisons). Additionally, no significant changes
were observed in any of these parameters after the inter-
vention (P > 0.05, within-group comparisons) (Table 3).
Discussion
To the best of our knowledge, this is the first randomized
controlled trial study aimed at investigating the effects of
an exercise training program in a cohort of C-SLE
patients. The main finding of this study is that a super-
vised aerobic exercise training program was safe and effec-
tive in improving the cardiorespiratory capacity in C-SLE
patients.
C-SLE is commonly associated with poor physical func-
tion and low levels of physical activity [11,12], possibly as a
consequence of reduced cardiorespiratory capacity [8-12]
and chronic fatigue [12]. Supporting this concept, we
observed lower cardiorespiratory capacity (for example,
lower peak VO2) and exercise tolerance (for example, lower
time-to-exhaustion in the cardiorespiratory exercise test) in
C-SLE patients when compared with their healthy peers.
Moreover, we showed for the first time that C-SLE patients
presented an abnormal HR response during and after the
cardiorespiratory test (for example, low CR and delayed HR
recovery), which are considered as important non-invasive
markers of autonomic dysfunction [37-39]. Our results are
in accordance with previous studies conducted with adult
SLE patients where the same abnormal pattern was evi-
denced [9,39]. Notably, there is evidence showing that, at
least in adult cohorts, low cardiorespiratory fitness and dys-
autonomia are associated with all-cause mortality and
increased cardiovascular risk [40,41]. However, these rela-
tionships remain to be proven in SLE cohorts. In this con-
text, strategies capable of improving the cardiorespiratory
capacity and counteracting autonomic dysfunction are of
upmost importance in the management of C-SLE patients
who are already at increased CVD risk [3,4].
Table 1 Demographic data at baseline
Variable C-SLE trained
(n = 10)
C-SLE non-trained
(n = 9)
Control
(n = 10)
Age, years 12.9 (2.3) 13.0 (1.8) 12.0 (1.8)
Body weight, Kg 48.7 (10.1) 49.7 (12.1) 46.6 (14.5)
Height, m 1.48 (0.09) 1.44 (0.11) 1.51 (0.13)
Body mass index, Kg/m2 22.3 (3.8) 23.9 (3.4) 21.2 (1.7)
Pubertal stages I/II/III/IV/V, number of individuals 1/2/2/2/3 0/2/3/2/2 3/2/1/2/2
SLEDAI-2K, score 5.3 (5.3) 5.6 (6.4) NA
SLICC/ACR-DI, score 0.4 (0.7) 0.4 (0.7) NA
Disease duration, years 3.3 (2.6) 4.3 (2.6) NA
Current dose of prednisone, mg/d 19.8 (17.0) 15.5 (7.7) NA
Cumulative dose of prednisone, g 13.7 (6.7) 20.9 (13.0) NA
Current dose of azathioprine, mg/d 128.6 (39.3) 121.4 (17.2) NA
Cumulative dose of azathioprine, g 58.2 (32.1) 62.2 (41.1) NA
Current dose of chloroquine, g/d 205.8 (51.2) 205.6 (51.2) NA
Cumulative dose of chloroquine, g 129.7 (119.9) 181.3 (121.5) NA
Drugs, number of patients (%)
Prednisone 10 (100) 9 (100)
Fluoxetine 1 (10) 0 (0) NA
Diltiazen 1 (10) 0 (0) NA
Enalapril 3 (30) 5 (55) NA
Losartan 1 (10) 1 (11) NA
Anlodipine 0 (0) 2 (22) NA
Carbamazepine 1 (10) 0 (0) NA
Methylphenidate 0 (0) 0 (0) NA
Clopidogrel 0 (0) 0(0) NA
Warfarin 1(10) 0(0) NA
Acetylsalicylic Acid 1 (10) 0 (0) NA
Results are presented as mean (SD) unless stated otherwise. C-SLE, childhood-onset systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease
activity index; SLICC/ACR-DI, Systemic Lupus International Collaborating Clinics/ACR Damage Index; NA, not applicable.
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Exercise has been shown to be a potential therapeutic
tool in the management of adult SLE. Three pilot studies
demonstrated that supervised exercise training can
alleviate fatigue in adult SLE patients [8,14,15]. Further-
more, Tench et al. [42] observed improvements in fatigue
after a three-month home-based exercise program. Simi-
larly, Carvalho et al. [16], reported beneficial effects of a
three-month exercise program on exercise tolerance,
aerobic conditioning (for example, increased VO2max),
and quality of life in SLE patients aged 18 to 55 years.
Although these studies point out the potential therapeu-
tic role of exercise in SLE, some limitations (such as lack
of a randomized control design and small sample sizes)
preclude definitive conclusions. Moreover, studies aimed
at investigating the effects of exercise on physical capa-
city in pediatric rheumatologic patients are still scarce.
Nonetheless, we have recently shown that a three-month
combined endurance and resistance exercise training
program induced improvements in the cardiorespiratory
capacity (for example, increased VO2 peak and time-to-
exhaustion), muscle strength, and physical function in
patients with JDM [23]. Furthermore, we also demon-
strated that a three-month supervised aerobic exercise
training program was capable of increasing VO2 peak
and time-to-exhaustion in a 15-year-old boy with anti-
phospholipid syndrome and C-SLE [25]. Importantly, the
current findings extend the previous observations on the
benefits of exercise in adult SLE and other pediatric
rheumatologic patients to C-SLE.
Specifically, we showed that a three-month aerobic
training program was effective in improving resting HR
and peak VO2, peak speed, and time-to-exhaustion in a
maximal graded exercise test in C-SLE patients. Notice-
ably, after the exercise training program, these para-
meters were comparable with those of their healthy
peers, suggesting that the exercise training was effective
in offsetting the C-SLE-related impairment in physical
function and aerobic capacity.
Accordingly, we demonstrated that the exercise train-
ing program was also effective in attenuating the
impaired CR and the delayed post-exercise HR recovery
in C-SLE patients, supporting the homeostatic role of
exercise in C-SLE, particularly regarding the autonomic
dysfunction. The present results corroborate the positive
effects of exercise training upon autonomic control in
adult patients with SLE [9] and CVD [43].
Children display a high bone turnover rate and a more
pronounced change in bone mass in response to exercise
training than later in life. In fact, we have previously
demonstrated that a short-term (12 weeks) exercise train-
ing program comprising aerobic and resistance exercises
was sufficient to increase BMAD in JDM patients [23].
Conversely, no changes in BMAD were observed in the
present study. This result is somewhat expected as the
C-SLE patients underwent only moderate-intensity aero-
bic exercise, which is unlikely to provide sufficient stimu-
lus to promote bone mass accretion. Therefore, future
Table 2 Exercise tolerance and cardiorespiratory
measurements before and after the exercise training
Variable C-SLE
trained
(n = 10)
C-SLE non-
trained
(n = 9)
Control
(n = 10)
Time-to-exhaustion,
minutes
PRE 10.1 (2.2)a 9.7 (1.6)a 13.7 (2.7)b
POST 12.8 (2.4)b 10.1 (1.8)a —
Resting heart rate, bpm
PRE 102.6 (10.3)a 106.1 (12.1)a 90.5 (15.7)b
POST 86.2 (13.8)b 110.6 (8.4)a —
Peak heart rate, bpm
PRE 178.2 (18.3)a 177.6 (17.4)a 195.8 (8.9)a
POST 183.6 (10.5)a 178.1 (18.6)a —
Peak VO2, ml/Kg/min
PRE 27.7 (6.1)a 25.7 (3.1)a 39.9 (7.3)b
POST 31.8 (8.0)b 25.8 (4.2)a —
Peak speed (Km/h)
PRE 4.4 (0.6)a 4.2 (0.5)a 5.4 (0.9)b
POST 5.2 (0.8)b 4.3 (0.5)a —
Chronotropic reserve, %
PRE 75.5 (18.7)a 74.8 (17.3)a 96.6 (8.2)b
POST 87.1 (9.0)b* 74.1 (18.9)a —
Heart rate, Δ%
Rest to VAT
PRE 29.8 (16.6)a 25.3 (12.0)a 60.0 (24.8)b
POST 56.3 (18.7)b 17.0 (9.5)a —
Rest to RCP
PRE 53.9 (13.7)a 54.9 (24.9)a 97.3 (35.9)b
POST 97.4 (28.6)b 42.8 (17.4)a —
Rest to Peak
PRE 75.3 (24.8)a 68.9 (22.9)a 122.6
(42.1)b
POST 117.7 (34.3)b 61.5 (16.6)a —
Heart rate recovery,
ΔHRR
ΔHRR1
PRE 25.5 (14.9)a 26.6 (10.0)a 40.2 (6.9)b
POST 41.5 (10.0)b 26.3 (8.0)a —
ΔHRR2
PRE 36.6 (10.2)a 35.6 (11.8)a 57.8 (8.9)b
POST 62.2 (13.7)b 39.8 (9.7)a —
Data are expressed as means (SD) (mixed model for repeated measures). Relative
change (Δ%) for heart rate was calculated for the intervals between rest to
ventilator anaerobic threshold (VAT), rest to respiratory compensation point
(RCP), and rest to peak of exercise. Absolute change (Δ) was used to calculate the
difference between heart rate at peak exercise and at the first (ΔHRR1) and
second minutes (ΔHRR2) after the exercise test. Means with different letters are
significantly different from each other (P < 0.05, between- or within-group
comparisons). *P = 0.06, within-group comparison. C-SLE, childhood-onset
systemic lupus erythematosus; PRE, pre-intervention (baseline), POST, post-
intervention; Peak, peak exercise; VO2, oxygen consumption.
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Figure 2 Cardiorespiratory measurements before (PRE) and after (POST) the exercise training. Dotted lines represent mean data from the
healthy control group at baseline. (A) Chronotropic reserve. (B) Absolute change in heart rate at the first minute after exercise (ΔHRR1). (C) Absolute
change in heart rate at the second minute after exercise (ΔHRR2). TR C-SLE, trained patients with childhood-onset systemic lupus erythematosus; NT
C-SLE, non-trained patients with childhood-onset systemic lupus erythematosus. Means with different letters are significantly different from each other: a,
significant difference when compared with the healthy control group; b, no significant difference when compared with the healthy control group.
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longer-term studies involving a more intensive aerobic
and resistance training exercises should be performed to
comprehensively examine the role of exercise on bone
mass in C-SLE patients.
Finally, it is important to emphasize that the exercise
training program did not provoke disease flare, as evi-
denced by lack of changes in disease activity scores and
laboratory parameters of inflammation. Additionally, the
drug regime was virtually unchanged throughout the
study and no other adverse events were reported. Collec-
tively, these findings suggest that a supervised moderate-
intensity aerobic training program may be safe for C-SLE
patients, supporting previous studies with adult SLE
patients [8,9,14,15].
This study presents some limitations. First, our sample
may be considered heterogeneous since the patients pre-
sented a large range of active disease scores. The selection
of patients with different active disease scores was inten-
tional and aimed at increasing the external validity of our
study. However, we acknowledge that the number of
patients enrolled in this trial did not allow us to compare
the potential differential responses of active and non-active
subjects to the exercise training. Therefore, further studies
with larger samples comparing the exercise responses as a
Figure 3 Cardiorespiratory measurements before (PRE) and after (POST) the exercise training. Dotted lines represent mean data from the
healthy control group at baseline. (A) Peak oxygen consumption (VO2 peak). (B) Relative change in heart rate (Δ%) between rest and the
ventilatory anaerobic threshold (VAT). (C) Relative change in heart rate (Δ%) between rest and the respiratory compensation point (RCP).
(D) Relative change in heart rate (Δ%) between rest and peak exercise (Peak). TR C-SLE, trained patients with childhood-onset systemic lupus
erythematosus; NT C-SLE, non-trained patients with childhood-onset systemic lupus erythematosus. Means with different letters are significantly
different from each other: a, significant difference when compared with the healthy control group; b, no significant difference when compared
with the healthy control group.
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function of active disease are indeed necessary. Second,
the healthy children did not participate in the exercise
training program, thus precluding any comparison
between patients and controls with respect to adaptive
responses to exercise (for example, magnitude of changes).
Finally, this was a short-term intra-hospital supervised
intervention. Further studies should investigate the effi-
cacy, safety and feasibility of other training program (such
as, recreational physical activity, sports-related activities,
physical education classes, and home-based programs).
Moreover, it is imperative to investigate the long-term
effects of exercise (or spontaneous physical activity) in
more robust outcomes (for example, incidence of institu-
tionalization, disease flares, health-related quality of life,
cardiovascular events and lipid and bone metabolism).
Conclusions
In conclusion, this study demonstrated for the first time
that a three-month supervised moderate-intensity aerobic
exercise training program can be safe and effective in
ameliorating the cardiorespiratory capacity and the auto-
nomic function in C-SLE patients. These findings stress
the potential role of exercise training in the management
of C-SLE, strengthening previous evidence of the benefi-
cial effects of exercise in other pediatric rheumatic
diseases.
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Table 3 Body composition, bone mineral apparent
density (BMAD) and bone mineral content (BMC) before
and after exercise training
Variable C-SLE
trained
(n = 10)
C-SLE non-
trained
(n = 9)
Control
(n = 10)
BMAD, L1-L4, g/cm3
PRE 0.097 (0.013) 0.108 (0.009) 0.113 (0.016)
POST 0.098 (0.012) 0.108 (0.010) —
BMAD, TF, g/cm3
PRE 0.133 (0.019) 0.145 (0.017) 0.163 (0.032)
POST 0.134 (0.020) 0.145 (0.021) NA
BMAD, WB without head, g/cm3
PRE 0.023 (0.001) 0.025 (0.002) 0.025 (0.002)
POST 0.024 (0.002) 0.024 (0.002) NA
Total BMC, g
PRE 1,223.0
(270.4)
1,186.2 (271.2) 1,530.0
(567.7)
POST 1.245.0
(262.7)
1,221.2 (252.7) NA
BMC, without head,
g
PRE 910.0 (233.1) 873.8 (267.4) 1,168.3
(508.0)
POST 927.0 (231.1) 916.3 (242.1) NA
Lean mass, Kg
PRE 31.5 (4.9) 29.9 (7.6) 33.9 (10.8)
POST 31.8 (5.1) 30.7 (7.4) NA
Fat mass, Kg
PRE 17.4 (7.3) 16.8 (6.0) 11.7 (7.2)
POST 17.0 (7.9) 19.1 (6.3) NA
Height, m
PRE 1.48 (0.09) 1.43 (0.9) 1.51 (0.13)
POST 1.49 (0.09) 1.44 (0.1) NA
Weight, Kg
PRE 48.7 (10.1) 49.7 (12.1) 46.6 (14.5)
POST 49.7 (11.3) 51.8 (13.3) NA
Data are expressed as means (SD) (mixed model for repeated measures).
C-SLE, childhood-onset systemic lupus erythematosus; PRE, pre-intervention
(baseline), POST, post-intervention; BMAD, bone mineral apparent density;
BMC, bone mineral content; TF, total femur; L1-L4, lumbar vertebrae L1 to L4;
WB, whole body; NA, not applicable. There were no significant differences
between or within groups for any of the variables.
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